search
Back to results

Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

Primary Purpose

Secondary Hyperparathyroidism

Status
Completed
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
KHK7580
Sponsored by
Kyowa Kirin Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Secondary Hyperparathyroidism focused on measuring Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

Eligibility Criteria

20 Years - 74 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent
  • Stable chronic renal disease patients receiving peritoneal dialysis for at least 16 weeks prior to the screening
  • intact parathyroid hormone value ≥ 240 pg/mL at the screening
  • Corrected serum calcium ≥ 8.4 mg/dL at the screening

Exclusion Criteria:

  • Patients with primary hyperparathyroidism
  • Patients who received cinacalcet within 2 weeks prior to the screening
  • Patients who began to take or changed the dose/dosing regimen of active vitamin D/its analogs, phosphate binders and/or calcium containing compounds within 2 weeks prior to the screening
  • Patients who underwent parathyroidectomy and/or parathyroid intervention
  • Patients with uncontrolled hypertension and/or diabetes
  • Patients with severe heart disorder
  • Patients with severe hepatic disease
  • Patients who take investigational drug in another clinical trial within 12 weeks prior to the screening
  • Patients who have been judged ineligible to participate in the study by the investigator

Sites / Locations

  • Kyowa Hakko Kirin

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

KHK7580

Arm Description

Outcomes

Primary Outcome Measures

Number and types of adverse events
The safety of KHK7580 assessed by number and types of adverse events, laboratory tests, vital signs and electrocardiogram

Secondary Outcome Measures

Profiles of pharmacokinetics
intact parathyroid hormone, whole parathyroid hormone, corrected serum calcium, phosphorus, intact fibroblast growth factor 23, ionized calcium, calcitonin

Full Information

First Posted
May 14, 2014
Last Updated
March 3, 2015
Sponsor
Kyowa Kirin Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT02143271
Brief Title
Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis
Official Title
A Single-dose Phase 1 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
May 2014 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kyowa Kirin Co., Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single administration of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal dialysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Secondary Hyperparathyroidism
Keywords
Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
KHK7580
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
KHK7580
Intervention Description
Oral administration
Primary Outcome Measure Information:
Title
Number and types of adverse events
Description
The safety of KHK7580 assessed by number and types of adverse events, laboratory tests, vital signs and electrocardiogram
Time Frame
For 8 days
Secondary Outcome Measure Information:
Title
Profiles of pharmacokinetics
Description
intact parathyroid hormone, whole parathyroid hormone, corrected serum calcium, phosphorus, intact fibroblast growth factor 23, ionized calcium, calcitonin
Time Frame
Pre-dose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72 and 168 hours post-dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent Stable chronic renal disease patients receiving peritoneal dialysis for at least 16 weeks prior to the screening intact parathyroid hormone value ≥ 240 pg/mL at the screening Corrected serum calcium ≥ 8.4 mg/dL at the screening Exclusion Criteria: Patients with primary hyperparathyroidism Patients who received cinacalcet within 2 weeks prior to the screening Patients who began to take or changed the dose/dosing regimen of active vitamin D/its analogs, phosphate binders and/or calcium containing compounds within 2 weeks prior to the screening Patients who underwent parathyroidectomy and/or parathyroid intervention Patients with uncontrolled hypertension and/or diabetes Patients with severe heart disorder Patients with severe hepatic disease Patients who take investigational drug in another clinical trial within 12 weeks prior to the screening Patients who have been judged ineligible to participate in the study by the investigator
Facility Information:
Facility Name
Kyowa Hakko Kirin
City
Tokyo
Country
Japan

12. IPD Sharing Statement

Learn more about this trial

Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

We'll reach out to this number within 24 hrs